These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34157774)

  • 1. [Biomarkers for renal cell tumours].
    Zeuschner P; Zaccagnino A; Junker K
    Aktuelle Urol; 2021 Sep; 52(5):452-463. PubMed ID: 34157774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possibilities of molecular diagnosis of renal cell carcinoma].
    Junker K
    Aktuelle Urol; 2014 Sep; 45(5):370-3. PubMed ID: 25230022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 4. [Novel biomarkers in renal cell carcinoma. Identification and functional characterization].
    Macher-Göppinger S
    Pathologe; 2015 Nov; 36 Suppl 2():201-4. PubMed ID: 26362327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
    Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
    Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic biomarkers in renal cell carcinoma.
    Jiang Z
    Expert Rev Mol Diagn; 2007 May; 7(3):293-307. PubMed ID: 17489736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future.
    Gan CL; Dudani S; Heng DYC
    Cancer J; 2020; 26(5):365-375. PubMed ID: 32947304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
    Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
    BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future prognostic factors for renal cell carcinoma: Workgroup No. 5. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).
    Swanson DA; Rothenberg HJ; Boynton AL; Consigliere D; Halling KC; Oda H; Smith D
    Cancer; 1997 Sep; 80(5):997-8. PubMed ID: 9307207
    [No Abstract]   [Full Text] [Related]  

  • 10. Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients.
    Fei H; Chen S; Xu C
    BMC Cancer; 2021 Apr; 21(1):411. PubMed ID: 33858375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personalised medicine in renal cell tumours].
    Junker K; Zeuschner P
    Aktuelle Urol; 2019 Sep; 50(5):513-523. PubMed ID: 31167243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).
    Li M; Wang Y; Song Y; Bu R; Yin B; Fei X; Guo Q; Wu B
    Oncol Rep; 2015 Apr; 33(4):1571-8. PubMed ID: 25682771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and prognosis of renal-cell tumors: a molecular approach.
    Wilhelm M; Krause U; Kovacs G
    World J Urol; 1995; 13(3):143-8. PubMed ID: 7550384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
    Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
    Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
    J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards individualized therapy for metastatic renal cell carcinoma.
    Kotecha RR; Motzer RJ; Voss MH
    Nat Rev Clin Oncol; 2019 Oct; 16(10):621-633. PubMed ID: 30992569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Escudier B; Eisen T; Porta C; Patard JJ; Khoo V; Algaba F; Mulders P; Kataja V;
    Ann Oncol; 2012 Oct; 23 Suppl 7():vii65-71. PubMed ID: 22997456
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomarkers of renal cell carcinoma.
    Ngo TC; Wood CG; Karam JA
    Urol Oncol; 2014 Apr; 32(3):243-51. PubMed ID: 24239464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.